Table 1.

Achievement of ASAS partial remission and ASDAS inactive disease with pharmacologic treatment in clinical trials.

Indication	Drug	Study	Timepoint	No. Patients	ASAS Partial Remission (%)	ASDAS Inactive Disease (%)	Reference
Axial SpA	Naproxen	INFAST	Week 28	51	35.3	19.6	Sieper, et al. Ann Rheum Dis 2014⁹
Nr-axSpA	Golimumab	—	Week 16	97	33	33	Sieper, et al. Arthritis Rheumatol 2015¹⁰
	Adalimumab	ABILITY-1	Week 12	91	16	24	Sieper, et al. Ann Rheum Dis 2013¹¹
	Certolizumab pegol	RAPID-axSpA	Week 12	200 mg: 46 400 mg: 51	200 mg: 28.3 400 mg: 29.4	200 mg: 30.4 400 mg: 25.5	Landewé, et al. Ann Rheum Dis 2014¹²
AS	Adalimumab	ATLAS	Week 12	208	20.7	36.5	van der Heijde, et al. Arthritis Rheum 2010¹³
	Etanercept	—	Week 24	138	17	—	Davis, et al. Arthritis Rheum 2003¹⁴
	Golimumab	GO-RAISE	Week 14	50 mg: 138	50 mg: ∼22^*	50 mg: 20.3	Inman, et al. Arthritis Rheum 2008¹⁵
				100 mg: 140	100 mg: ∼20^*	100 mg: 23.7	van der Heijde, et al. J Rheumatol 2015¹⁶
	Infliximab	ASSERT	Week 24	201	22.4	—	van der Heijde, et al. Arthritis Rheum 2005¹⁷
				163	23.3	31.9	Machado, et al. Ann Rheum Dis 2011¹⁸
	Certolizumab pegol	RAPID-axSpA	Week 12	200 mg: 65 400 mg: 56	200 mg: 20 400 mg: 19.6	200 mg: 21.5 400 mg: 16.1	Landewé R, et al. Ann Rheum Dis 2014¹² (mixed anti-TNF-naive and anti-TNF-IR population)
	Secukinumab	MEASURE 1	Week 16	75 mg: 124 150 mg: 125 TNF-naive 75 mg: 90 150 mg: 92 TNF-IR 75 mg: 34 150 mg: 33	75 mg: 16 150 mg: 15 TNF-naive 75 mg: 20 150 mg: 16.3 TNF-IR 75 mg: 5.9 150 mg: 12.1	—	Baeten, et al. N Engl J Med 2015⁷; Baeten, et al. Arthritis Rheumatol 2015¹⁹
		MEASURE 2	Week 16	75 mg: 73 150 mg: 72 TNF-naive 75 mg: 45 150 mg: 44 TNF-IR 75 mg: 28 150 mg: 28	75 mg: 15 150 mg: 14 TNF-naive 75 mg: 20 150 mg: 18.2 TNF-IR 75 mg: 7.1 150 mg: 7.1	—	Baeten, et al. N Engl J Med 2015⁷; Sieper, et al. Ann Rheum Dis 2017²⁰

↵* Value estimated from graph in manuscript; data not cited in text. ASAS: Assessment of SpondyloArthritis international Society; ASDAS: Ankylosing Spondylitis Disease Activity Score; TNF-IR: tumor necrosis factor inhibitor inadequate responder; TNF-naive: TNF inhibitor naive; SpA: spondyloarthritis; nr-axSpA: nonradiographic axial SpA.